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Identification of the basolateral targeting determinant of a
peripheral membrane protein, MacMARCKS, in polarized cells
Monn Monn Myat*†, Sandy Chang*, Enrique Rodriguez-Boulan‡ and
Alan Aderem†
Background: Although the molecular determinants that specify the targeting of
transmembrane proteins to the apical or basolateral membrane domains within
polarized epithelial cells have been well characterized, very little is known about
the targeting of peripheral membrane proteins within these cells. MacMARCKS
is a member of the MARCKS family of protein kinase C (PKC) substrates. This
myristoylated protein regulates actin structure at cell membranes and is
essential for the morphogenic movement of neuroepithelial cells during the
formation of the neural tube.
Results: MacMARCKS was specifically targeted to sites of cell–cell contact in
the basolateral domain of polarized Madin–Darby canine kidney (MDCK)
epithelial cells and was displaced from this location upon activation of PKC. We
defined the basolateral targeting determinant of MacMARCKS to be the
effector domain, a basic region spanning 24 amino acids and containing the
PKC phosphorylation sites as well as binding sites for calmodulin and actin.
This domain, in conjunction with a myristoyl moiety, was sufficient to target a
non-membrane-associated protein — green fluorescent protein — specifically to
the basolateral surface of polarized MDCK cells.
Conclusions: This is the first description of a specific amino acid sequence
that specifies targeting of a peripheral membrane protein to the basolateral
membrane in polarized epithelial cells.
Background
Cell polarity reflects an asymmetric distribution of
plasma membrane constituents; often the membrane is
divided into two or more domains which have different
protein and lipid compositions [1–3]. The maintenance
of cell polarity is crucial in specifying a variety of bio-
logical processes including embryonic development,
differentiation, activation of the immune response, and
vectorial transport of ions and solutes across cells [1–3].
Epithelial cells form a layer at the interface between
the organism and the environment, or between an organ
and a fluid space, and their polarized morphology facili-
tates their function both as a physical barrier and as a
transport system. In general, polarized epithelial cells
have distinct apical and basolateral domains. Although
the molecular determinants that specify apical or baso-
lateral targeting of transmembrane proteins within
polarized epithelial cells have been well characterized,
little is known about the targeting of peripheral mem-
brane proteins to apical and basolateral domains within
these cells. 
MacMARCKS (also known as MARCKS related protein,
MRP) is a member of the MARCKS family of protein
kinase C (PKC) substrates and has been implicated in
regulating adhesion, phagocytosis, membrane trafficking
and the morphogenic movements accompanying embry-
onic development [4–6]. The protein has a basic effector
domain which contains the serine residues that are phos-
phorylated by PKC and which binds calcium–calmodulin,
F-actin and acidic phospholipids such as phosphatidyl-
inositol 4,5-bisphosphate (PIP2) [4,7,8]. MacMARCKS is
myristoylated at its amino terminus and it binds to mem-
branes using the cooperative binding energies con-
tributed by the insertion of the myristic acid moiety into
the lipid bilayer and by the interaction of the basic effec-
tor domain with phospholipids [4,9,10]. Deletion of the
MacMARCKS gene in mice prevents cranial neurulation,
and this is thought to be due to a defect in actin-based
shape changes of the neuroepithelial cells that form the
dorsolateral hinges of the developing neural tube [11,12].
The phenotype of the MacMARCKS null mouse
prompted us to examine the biology of MacMARCKS in
epithelial cells. Here, we report that MacMARCKS is
specifically targeted to the basolateral membrane of
Madin–Darby canine kidney (MDCK) epithelial cells
and that it is displaced from this location after activation
of PKC. We also demonstrate that the basolateral target-
ing determinant of MacMARCKS is contained within its
effector domain. 
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Results and discussion
MacMARCKS is targeted to the basolateral membrane
MacMARCKS is expressed endogenously in the MDCK
epithelial cell line; a polyclonal MacMARCKS-specific anti-
serum immunoprecipitated a protein of the appropriate
molecular mass from 3H-myristic-acid-labeled MDCK cell
lysates (Figure 1, lane 2). As expected, the phosphorylation
of MacMARCKS was increased upon activation of PKC
(Figure 1, lanes 3,4), and peptide mapping confirmed that
the known PKC phosphorylation sites, serines 93 and 104,
were phosphorylated ([4,7]; data not shown). In MDCK
cells, serine 101 is not phosphorylated by PKC, and this was
confirmed by the demonstration that mutation of serines 93
and 104 resulted in a nonphosphorylatable protein (data not
shown). In the absence of PKC activation, approximately
90% of total cellular MacMARCKS protein partitioned with
the membrane fraction (Figure 1, lanes 5,6). Upon activa-
tion of PKC, only an additional 5–10% of MacMARCKS
was released from the membrane to the cytosol (Figure 1,
lanes 7,8). This minimal release of MacMARCKS from the
membrane has been noted previously in synaptosomes and
PC12 cells [13] and contrasts with the release of the related
MARCKS protein that is quantitatively released from the
membrane when it is phosphorylated by PKC [9,14]. The
difference in membrane-binding properties between
MARCKS and MacMARCKS might be ascribed to the
additional phosphorylation site in the effector domain of
MARCKS and to the increased distance between the
amino-terminal myristoyl moiety and the effector domain of
the MARCKS protein [9]. 
In polarized MDCK cells, endogenous MacMARCKS
(Figure 2a) localized to sites of cell–cell contact in the
basolateral membrane, where co-staining of MacMARCKS
and the adhesion protein E-cadherin was observed
(Figure 2b). Additional MacMARCKS staining was also
seen on intracellular vesicles in the basolateral domain
(Figure 2a). The localization of MacMARCKS to sites of
cell–cell contact depended upon ligated E-cadherin
(Figure 2c–f). Homotypic interaction between cadherin
molecules is calcium-dependent; in low calcium media
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Figure 1
MacMARCKS is expressed endogenously in MDCK cells as analyzed
by 3H-myristic-acid-labeling followed by SDS–PAGE and
autoradiography. Canine MacMARCKS was immunoprecipitated
(lane 2) from 3H-myristic-acid-labeled MDCK cell lysates (lane 1) using
an anti-murine MacMARCKS polyclonal antiserum (see Materials and
methods). The PKC-mediated phosphorylation of MacMARCKS
increased in cells treated with phorbol myristate acetate, PMA (lane 4)
compared with untreated cells (lane 3). In untreated MDCK cells
(lanes 5,6), approximately 90% of total 3H-myristic acid-labeled
MacMARCKS was found in the membrane fraction (M), and 10% was
found in the cytosol (C). In cells treated with PMA (lanes 7,8),
approximately 80% of MacMARCKS was found associated with the
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Figure 2
MacMARCKS is targeted to the basolateral membrane in polarized
MDCK cells as revealed by immunofluorescence staining of (a,c,e)
MacMARCKS and (b,d,f) E-cadherin, a component of the adherens
junctions in the basolateral domain. (a,b) In polarized MDCK cells
grown on filter supports for 5 days, endogenous MacMARCKS was
found in the basolateral domain at sites of cell–cell contact, where it
colocalized with E-cadherin. MacMARCKS also localized to a
population of basolateral vesicles. (c,d) When MDCK cells were
incubated for 18 h in low calcium medium, MacMARCKS and 
E-cadherin were found on intracellular vesicles. (e,f) Upon switching
the cells from low calcium medium to normal calcium medium,
MacMARCKS and E-cadherin once again colocalized at sites of
cell–cell contact.
cell–cell contacts are not formed [15]. In cells lacking
cell–cell contact due to incubation in low calcium media,
MacMARCKS and E-cadherin were distributed through-
out the cell in a vesicular pattern (Figure 2c,d). Upon
addition of calcium to the medium, cell–cell contacts
formed and MacMARCKS and E-cadherin were redistrib-
uted to sites of cell–cell contact (Figure 2e,f). 
Identification of the basolateral targeting determinant of
MacMARCKS
In order to identify the basolateral targeting domain of
MacMARCKS, a series of hemagglutinin (HA) epitope-
tagged mutant molecules were constructed (Figure 3), and
stably expressed in MDCK cells. HA-tagged wild-type
MacMARCKS (WT-MM) colocalized with E-cadherin at
sites of cell–cell contact in the basolateral domain in an
identical pattern to the endogenous protein, indicating
that the HA epitope did not interfere with targeting
(Figure 4a,b). Pixel intensity measurements revealed that
more than 90% of MacMARCKS was localized to the
basolateral domain (Figure 4h). The targeting of Mac-
MARCKS to the basolateral membrane was confirmed
biochemically in purified basolateral and apical mem-
branes [16]. Densitometric measurements showed that
approximately 70% of MacMARCKS partitioned with
basolateral membranes, 25% associated with apical mem-
branes, and 5% was found in the cytosol (Figure 4g and
data not shown). The 25% of MacMARCKS found in the
apical membranes was probably due to contamination of
this preparation with basolateral membranes, because it
paralleled the distribution of E-cadherin (approximately
20%; Figure 4g and data not shown). Extraction of MDCK
cells with 0.5% Triton X-100 showed that 40% of Mac-
MARCKS (Figure 4c) remained associated with the baso-
lateral cytoskeleton identified by E-cadherin (Figure 4d
and data not shown).
The MH2 domain and the effector domain of Mac-
MARCKS are highly conserved among different species
[7]. The MH2 domain does not participate in targeting
MacMARCKS to the basolateral membrane, because an
HA-tagged mutant version of MacMARCKS that lacks
the MH2 domain (MM-∆MH2) was targeted to the
basolateral membrane (Figure 4e,f). This result was
confirmed by analyzing purified apical and basolateral
membrane preparations and by a pixel intensity profile
of optical sections of MDCK cells (Figure 4g,i). 
Activation of PKC by phorbol esters prevented the spe-
cific targeting of MacMARCKS to the basolateral mem-
brane, thereby allowing it to be distributed to both the
apical and the basolateral membranes (Figure 5). PKC
activation did not alter the expression level of Mac-
MARCKS, nor was the redistribution of MacMARCKS
affected by protein synthesis inhibitors, indicating that the
MacMARCKS found in the apical membranes was not
derived from new protein synthesis (data not shown). To
assess the role of MacMARCKS phosphorylation in pre-
venting its specific association with the basolateral
cytoskeleton, we generated a nonphosphorylatable form of
MacMARCKS. This was achieved by mutating serines 93
and 104, which are phosphorylated by PKC in MDCK
cells, to alanine residues (M.M.M., E.R-B. and A.A.,
unpublished observations). This nonphosphorylatable
MacMARCKS mutant was also not targeted exclusively to
the basolateral membrane, and instead localized to the
entire plasma membrane (M.M.M., E.R-B. and A.A.,
unpublished observations). In data to be reported else-
where, we demonstrate that MDCK cells expressing the
nonphosphorylatable MacMARCKS mutant are unable to
establish normal polarity, rendering it impossible to
compare the localization of the mutant MacMARCKS to
its wild-type counterpart. This therefore suggests that
phosphorylation of MacMARCKS abrogates its specific
targeting to the basolateral membrane. It is also possible
that PKC phosphorylates other cellular components that
prevent the specific localization of MacMARCKS to the
basolateral membrane. 
Targeting of MacMARCKS–GFP fusion proteins
The observations described above implicate the effector
domain in basolateral targeting of MacMARCKS, as phos-
phorylation of this region disrupts the restriction of the
protein to the basolateral domain. An effector domain 
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Figure 3
Schematic diagram of wild-type and mutant MacMARCKS proteins,
and green fluorescent protein (GFP) fusion proteins. Wild-type
MacMARCKS (WT-MM) was epitope-tagged at the carboxyl terminus
with the 9 amino-acid hemagglutinin (HA) epitope tag. ∆MH2-MM
represents a deletion mutant of WT-MM, lacking the MH2 domain.
My–GFP contains 12 amino acids of the myristoylation sequence of
recoverin (My) fused to the amino terminus of GFP. GFP—ED contains
the effector domain (ED) of MacMARCKS fused to the carboxyl
terminus of GFP. My–GFP–ED represents GFP flanked at the amino
terminus with the recoverin myristoylation sequence and at the


















deletion mutant of MacMARCKS could not be expressed
in MDCK cells (data not shown). We therefore attempted
to target green fluorescent protein (GFP) to the basolateral
domain by fusing it to the effector domain of Mac-
MARCKS. GFP alone was not targeted to a distinct
domain in polarized MDCK cells, and instead was found in
a diffused pattern throughout the cytoplasm (Figure 6a).
Fusion of the MacMARCKS effector domain to the car-
boxyl terminus of GFP (GFP–ED; see Figure 3) targeted
the fusion protein to the nucleus (Figure 6b). This occurs
because the basic effector domain resembles a nuclear
localization signal, which is usually masked by the carboxyl
terminus of MacMARCKS (A.A., unpublished observa-
tions). Because myristoylation is absolutely required for
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Figure 4
Localization of HA-tagged wild-type and
∆MH2 MacMARCKS. Immunofluorescence
staining of (a,c,e) MacMARCKS proteins and
(b,d,f) E-cadherin in transfected MDCK cells.
(a,b) WT-MM colocalized with E-cadherin at
sites of cell–cell contact in the basolateral
domain. (c,d) In cells extracted with 0.5%
Triton X-100, a pool of WT-MM remained
Triton-insoluble on the basolateral membrane
marked by E-cadherin. (e,f) ∆MH2-MM also
colocalized with E-cadherin at sites of
cell–cell contact in the basolateral domain.
(g) Immunoblot of the apical marker gp135,
the basolateral marker E-cadherin, and WT-
MM and ∆MH2-MM in purified apical (Ap) and
basolateral (Bl) membranes. (h,i) Pixel
intensity profiles of MDCK cells expressing
(h) WT-MM or (i) ∆MH2-MM. SIM represents

























































Activation of PKC prevents the specific
targeting of MacMARCKS as revealed by
immunofluorescence staining of (a,c,e,g) WT-
MM and (b,d,f,h) the apical marker gp135 in
(a,b,e,f) apical sections and (c,d,g,h)
basolateral sections of MDCK cells. (a–d) In
control untreated MDCK cells (–PMA), WT-
MM was absent from the apical domain,
marked by gp135, and was present in the
basolateral domain where gp135 was absent.
(e–h) In PMA-treated cells (+PMA), WT-MM
was found in the apical domain marked by
gp135, and in the basolateral domain where
gp135 was absent. The apical optical
sections identified by the gp135 marker were
separated by 6 µm from the basolateral
sections identified by E-cadherin (data not
shown). Ap, apical; Bl, basolateral.
(a) (b) (e) (f)






the membrane binding of MacMARCKS, we added a
myristoyl moiety to the GFP–ED fusion protein
(My–GFP–ED; see Figure 3) to determine whether mem-
brane binding is a requisite for basolateral targeting. The
myristoylation consensus sequence of the unrelated
protein, recoverin [17], was used to avoid introducing pos-
sible targeting signals of MacMARCKS that may reside at
its amino terminus. Indeed, the MacMARCKS effector
domain, in conjunction with a generic myristoylation
sequence, targeted GFP to sites of cell–cell contact in the
basolateral domain, as well as to the nucleus (Figure 6c),
but not to the apical domain (data not shown). Activation of
PKC resulted in the phosphorylation of My–GFP–ED, and
prevented its association with the basolateral membrane
(data not shown). However, in these cells the bulk of the
fusion protein was still found in the nucleus (data not
shown). Most of the nuclear fraction of the My–GFP–ED
fusion protein was not myristoylated (data not shown).
Myristoylated GFP lacking the MacMARCKS effector
domain (My–GFP; see Figure 3) associated mainly with
intracellular membranes (Figure 6d and data not shown).
Conclusions
The effector domain of MacMARCKS targets the protein to
the basolateral membrane of polarized cells. PKC-mediated
phosphorylation of this domain prevents this interaction and
allows the protein to distribute randomly on cellular mem-
branes. PKC activation in polarized MDCK cells is accom-
panied by weakened cell–cell interactions, as evidenced by
decreased electrical resistance across the monolayer [18,19].
In data to be reported elsewhere, we show that expression
in MDCK cells of a MacMARCKS mutant in which the
PKC phosphorylation sites within the effector domain have
been changed from serine to alanine profoundly modifies
cell–cell contact. Thus, targeting of MacMARCKS to sites
of cell–cell contact at the basolateral membrane of polar-
ized epithelial cells places it in the correct context to
mediate the effects of PKC on cell–cell adhesion.
Materials and methods
Radiolabeling and immunoprecipitation of MacMARCKS
MDCK cells, grown to confluence on plastic dishes, were incubated
overnight with 40 µCi/ml 3H-myristic acid [7]. For 32P-orthophosphate
labeling, MDCK cells were incubated in phosphate-free RPMI (Life
Technologies) for 1.5 h, and labeled for 1.5 h with 0.1 mCi 32P-
orthophosphate per confluent 35 mm dish of cells. Where indicated,
labeled cells were treated with 200 nM PMA for 30 min prior to lysis
[7]. Immunoprecipitations of MacMARCKS from radiolabeled MDCK
cell lysates were performed using a polyclonal antibody raised against a
purified GST–MacMARCKS fusion protein [7], as previously described
[13]. Two-dimensional thermolytic phosphopeptide mapping of Mac-
MARCKS immunoprecipitated from MDCK cells was carried out as
described previously [7]. Protein synthesis was inhibited by incubating
MDCK cells with 0.05 mg/ml cycloheximide for 1 h and immunoblotting
the cell lysates for MacMARCKS as described previously [13]. 
Fractionation of MDCK cells
MDCK cells were disrupted by hypotonic shock by placing them in a
buffer containing 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM EGTA,
0.09 TIU/ml aprotinin, 0.5 mg/ml leupeptin, and 1 mM PMSF. Bulk
membrane and cytosol fractions were prepared by centrifuging the
lysed cells at 100,000 × g for 30 min to separate the cytosol fraction
(supernatant) from the membrane fraction (pellet). The membrane
pellet was resuspended in the homogenization buffer, and equivalent
amounts of protein were analyzed by SDS–PAGE and immunoblotting.
The amount of MacMARCKS in the cytosol and membrane fraction
was quantified by densitometry. 
Immunofluorescence
MDCK cells grown in DMEM with 1% L-glutamine, 100 U/ml penicillin
G, 100 µg/ml streptomycin (all from JRH Biosciences) and 10% heat-
inactivated FBS (HyClone), were plated at a density of 1× 105 cells per
12 mm Transwell filter insert (Costar) and allowed to grow for 5 days
before processing for microscopy. Cells were fixed in 2% paraformalde-
hyde and permeabilized in 0.075% saponin. After blocking in PBS sup-
plemented with 0.1 mM CaCl2, 1 mM MgCl2, and 0.05% milk, cells
were incubated in primary and secondary antibodies. Processed filters
were then mounted onto microscope slides in Vectashield (Vector Lab-
oratories). Endogenous MacMARCKS was detected with an affinity-
purified polyclonal antibody raised against a purified
GST–MacMARCKS fusion protein [7]. HA-tagged MacMARCKS pro-
teins were detected with a polyclonal rabbit anti-HA antibody (Babco).
E-cadherin was detected with a pan-cadherin antibody (Sigma) and
gp135 with a monoclonal anti-gp135 antibody (a kind gift of G.
Ojakien). F-actin was detected either with FITC–phalloidin or
TRITC–phalloidin (Molecular Probes). Rabbit polyclonal antibodies
were visualized with either a Texas-red-conjugated goat anti-rabbit sec-
ondary antibody (Molecular Probes) or a FITC-conjugated goat anti-
rabbit (Fab′2) immunoglobulin (Ig) G antibody (Tago) and mouse
monoclonal antibodies were visualized with a FITC-conjugated goat
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Figure 6
The effector domain of MacMARCKS targets myristoylated GFP to the
basolateral domain. MDCK cells were transfected with the GFP
constructs shown in Figure 3. (a) GFP alone was found in a diffuse
pattern in the cytoplasm, whereas (b) GFP–ED was targeted to the
nucleus. (c) My–GFP–ED was targeted to sites of cell–cell contact
in the basolateral domain, and was also found in the nucleus.
(d) My–GFP localized exclusively to intracellular membranes. 
anti-mouse IgG plus IgM antibodies (Jackson ImmunoResearch Labora-
tories) or Texas-red-conjugated goat anti-mouse antibodies (Molecular
Probes). Where indicated, cells were treated with 200 nM PMA (LC
Services), for 30 min prior to processing for immunofluorescence. Cells
containing GFP fusion proteins were fixed and mounted onto micro-
scope slides as described above. 
Confocal microscopy and measurement of pixel intensity
profiles
Confocal images were acquired using a Zeiss Axiovert microscope and
the MRC-1024 Lasersharp software (Bio-Rad Laboratories). For mea-
surements of pixel intensity profiles, a series of 0.2 µm confocal optical
sections were acquired and the pixel intensity profiles of selected areas
were obtained using the MRC-1024 Lasersharp Software. The sum of
intensity measurements/µm2 was quantitated and graphs were gener-
ated using Microsoft Excel software. 
Calcium switch assay
MDCK cells were plated at 1 × 105 cells per 12 mm Transwell filter and
allowed to adhere for 2 h in DMEM (10% FBS) containing a normal
concentration (1.8 mM) of calcium. Cells were then washed gently in
low calcium medium (LCM; MEM modified for suspension cultures
which lacks CaCl2 and contains less than 5 µM Ca2+, Gibco BRL).
Cells were incubated for 18 h in LCM containing dialyzed 5% FBS
(Gibco BRL). The calcium switch was begun by replacing LCM with
DMEM (1.8 mM Ca2+) containing 10% FBS for the indicated times
before visualization by microscopy. 
Generation of MacMARCKS mutants and their expression in
MDCK cells
A wild-type MacMARCKS cDNA construct (WT-MM) containing a HA
epitope YPYDVPDYA sequence (in single-letter amino acid code) at the
3′ end was generated by PCR using the 5′ oligo A1 5′-GCGGGATC-
CATGGGCAGCCAGAGCTCT-3′ and the 3′ oligo A2 5′-GCGGG-
ATCCTCACAAGCTAGCGTAATCTGGAACATCGTATGGGTACTCAT
TCTGCTCAGCACT-3′. Mouse MacMARCKS cDNA [7] served as the
template. For high levels of expression in MDCK cells, all HA-tagged
constructs were subcloned into the pcDNA3 vector (Invitrogen) under
the control of the cytomegalovirus promoter. The serine to alanine muta-
tions within the MacMARCKS effector domain (nonphosphorylatable
MacMARCKS) were generated using two DNA fragments spanning this
domain that were generated by PCR using WT-MM as the template. The
first fragment encoded amino acids 1–100, and was generated with the
5′ A1 oligo and 3′ B1 oligo (5′-AAGCTTGAAAGGCTTCTTGAAACGA-
GAATTTCTTC-3′), and the second DNA fragment encoded amino acids
99–200 as well as the 11 amino acid HA epitope, and was generated
with the 5′ B2 oligo 5′-AAGCTTAGTGGCCTGGCCTTCAAGAGAAAT-
3′) and the 3′ A2 oligo. All PCR reaction products were subcloned into
pBlueScript. For construction of the ∆MH2-MM mutant, an MluI site
was engineered into PCR primers to generate a PCR fragment con-
taining sequences carboxy-terminal of the MH2 domain. This fragment
was then ligated to the existing MluI site at the amino terminus of the
MH2 domain.
To generate the My–GFP construct, the MMXC1oligo (5′-
AATTCATGGGAACAGCAAGAGTGGGGCCCTGCA-3′), and the
MMXC2 oligo (5′-GGGCCCCACTCTTGCTGTTCCCCATG-3′) that
corresponded to the amino-terminal myristoylation sequence of recov-
erin [17] were annealed and linked to the 5′ end of the GFP gene in the
pEGFP vector (Clontech). To generate the GFP–ED construct, the
effector domain of MacMARCKS was first obtained by PCR using the
MMXC3 (5′-ATTGTACAAGGGGGAGGTCGCCCCCAAGGAG-3′)
and MMXC4 (5′-ATTGTACATTATCACCCCCACCCGCCGGC-3′)
oligos, and wild-type HA-tagged MacMARCKS as the template. The
effector domain was then ligated onto the 3′ end of the GFP gene in
the pEGFP vector. The My–GFP–ED construct was generated by ligat-
ing the effector domain of MacMARCKS to the 3′ end of the My–GFP
construct. For high levels of expression in MDCK cells, all HA-tagged
constructs were subcloned into the pcDNA3 vector (Invitrogen) under
the control of the cytomegalovirus promoter. Stable MDCK cell lines
were generated using the calcium-phosphate transfection method [20].
Triton X-100 extraction
For immunofluorescence, polarized MDCK cells grown on Transwell
filters were extracted in CSK (cytoskeleton) buffer (150 mM NaCl,
50 mM Tris-HCl, pH 7.5, 0.01% NaN3, 2 mM EDTA with protease
inhibitors, aprotinin, leupeptin and PMSF) with 0.5% Triton X-100 for
10 min at 4°C, and washed twice with PBS-CM (PBS supplemented
with 0.1 mM CaCl2 and 1 mM MgCl2) before being processed for
immunofluorescence. For immunoblots, polarized cells grown for
5 days on 12 mm Transwell filters were extracted in CSK buffer as
described above and cell lysates were centrifuged at 48,000 rpm for
10 min. The supernatants (Triton-soluble) were removed, and the
Triton-insoluble pellets were resuspended in CSK buffer. Equivalent
amounts of total protein for Triton-soluble and Triton-insoluble samples
were analyzed by immunoblotting, as described above. 
Purification of apical and basolateral membranes
Semi-purified apical and basolateral membranes were obtained as
described previously [16]. Cells grown on 24 mm Transwell filters
(Corning) were coated with cationized colloidal silica (a kind gift of B.
Jacobson) in Mes/saline (Sigma) and polyacrylic acid (Polysciences),
and overlaid with a glass slide that had been previously coated with
poly-L-lysine (Sigma). The filter and the glass slide were pressed
together using a rolling pin, the filter was peeled apart rapidly, and the
transferred apical membranes on the glass slide were scraped into
homogenization buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA, and
1 mM EGTA). The apical membranes were precipitated in 10% TCA
and washed three times with –20°C acetone. Equivalent amounts of
total protein for apical and basolateral samples were analyzed by
immunoblotting as described previously [13]. E-cadherin, gp135, HA-
tagged proteins, wild-type and ∆MH2-MM MacMARCKS were
detected with the antibodies described above. 
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